Brookmont Capital Management lowered its holdings in shares of Stryker Co. (NYSE:SYK) by 14.5% during the 4th quarter, Holdings Channel reports. The firm owned 5,115 shares of the medical technology company’s stock after selling 864 shares during the quarter. Brookmont Capital Management’s holdings in Stryker were worth $792,000 at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in SYK. Sawyer & Company Inc bought a new position in shares of Stryker during the 4th quarter valued at $125,000. Sit Investment Associates Inc. grew its holdings in shares of Stryker by 114.3% during the 4th quarter. Sit Investment Associates Inc. now owns 825 shares of the medical technology company’s stock valued at $128,000 after purchasing an additional 440 shares during the last quarter. San Francisco Sentry Investment Group CA grew its holdings in shares of Stryker by 47.8% during the 3rd quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock valued at $143,000 after purchasing an additional 325 shares during the last quarter. Oak Point Wealth Management bought a new position in shares of Stryker during the 4th quarter valued at $145,000. Finally, Dubuque Bank & Trust Co. bought a new position in shares of Stryker during the 4th quarter valued at $164,000. 74.49% of the stock is currently owned by institutional investors.
In other news, insider Graham A. Mclean sold 2,984 shares of the firm’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $160.53, for a total value of $479,021.52. Following the completion of the sale, the insider now directly owns 9,100 shares of the company’s stock, valued at approximately $1,460,823. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Howard E. Cox, Jr. sold 7,400 shares of the firm’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $164.09, for a total transaction of $1,214,266.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 16,840 shares of company stock valued at $2,749,989. Corporate insiders own 7.40% of the company’s stock.
Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 30th. The medical technology company reported $1.96 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.95 by $0.01. Stryker had a net margin of 8.20% and a return on equity of 24.56%. The firm had revenue of $3.47 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same period last year, the company posted $1.78 EPS. The company’s quarterly revenue was up 9.9% compared to the same quarter last year. research analysts predict that Stryker Co. will post 7.12 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be given a $0.47 dividend. The ex-dividend date is Wednesday, March 28th. This represents a $1.88 annualized dividend and a dividend yield of 1.13%. Stryker’s dividend payout ratio is 38.37%.
Several equities analysts recently commented on the stock. Morgan Stanley increased their target price on shares of Stryker from $179.00 to $186.00 and gave the company an “overweight” rating in a report on Monday. Needham & Company LLC reissued a “hold” rating on shares of Stryker in a report on Wednesday, January 31st. Oppenheimer set a $156.00 price target on shares of Stryker and gave the stock a “hold” rating in a report on Monday, October 30th. ValuEngine raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, November 14th. Finally, Cantor Fitzgerald reissued a “hold” rating and issued a $163.00 price target on shares of Stryker in a report on Tuesday, January 30th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $163.80.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.